Posts tagged ‘PI3K cancer’
After a hectic ASCO 2012, the next conference we will be attending is The New York Academy of Sciences (NYAS), Inositol Phospholipid Signaling in Physiology and Disease event on June 26 -27, 2012 in New York.
The NYAS often run events that are on a par with the American Association for Cancer Research (AACR), where leading researchers present their early-stage findings to the science community. Cancer signaling pathways are complex and understanding basic science in this area is key to rational drug development and target identification.
The keynote lecture is by Lewis Cantley, who will speak on “Phosphoinositol Signaling and Disease.” Of the many interesting topics from a new product development perspective that will be discussed, a few that caught our attention include:
- Lloyd Trotman, PTEN Activity
- Neil Rosen, Mechanisms of PI3K Inhibition in Cancer
- David Solit, Interrupting the PI3K-AKT-mTOR Pathway in Cancer Therapy
Researchers from Novartis and Gilead will also discuss some of the challenges in clinical development and targeting PI3Kδ in lymphoid malignancies.
If you are interested in the PI3-kinase area for drug development or want to learn more about the where the cutting edge of cancer research is at in this area, then the NYAS event on inositol phospholipid signaling looks well worth attending.
Icarus Consultants is delighted to be a promotional partner with The New York Academy of Sciences for this event, and in return we can offer readers a 15% discount on the cost of meeting registration. Use the special code INOSITOL15 when making your booking – please note this does not apply to existing registrations.
If you can’t make it to New York, Sally Church will be writing about it on Pharma Strategy Blog, unless a budding young scientist attending the meeting would like to write a guest post – if that’s you, then please do contact us and we would be delighted to hear from you!
Update June 28, 2012
The New York Academy of Sciences meeting was well worth attending.
Sally Church, PhD has written about data presented at the meeting on PI3K delta and Bruton’s Tyrosine Kinase (BTK) inhibitors in development for CLL & NHL.
In her Pharma Strategy Blog post, Sally discusses some of the challenges and opportunities for GS-1101 (formerly CAL-101) and ibrutinib.
Future advances in cancer drug development may come from targeting cancer metabolism and the pathways associated with this.
Image Source: Tak W Mak, Stockholm EMCC 2011
That was one of the key messages of Tak Wah Mak (Princess Margaret Hospital, Toronto) in his plenary presentation at the recent ESMO/ECCO multidisciplinary cancer congress in Stockholm.
An examples of this is the PI3-Kinase RAS axis that also inhibits glycolysis.
Sally Church in today’s post on Pharma Strategy Blog picks up on this, and how “understanding the process of tumorigenesis, ie tumour formation and growth, is critical to figuring out how to stop it.”
She discusses recent research from MD Anderson Cancer Center on Pyruvate Kinase M2 (PKM2) that is highly expressed in human cancer.
PKM2 plays an important role in glycolysis (Warburg effect) but also has a non-metabolic effect on tumor formation and growth.
The MD Anderson researchers showed how epidermal growth factor (EGFR) activation led to translocation of PKM2, but not PKM1.
You can read more on Pharma Strategy Blog about the significance of these findings and how this might lead to new biomarkers and treatment approaches.
Targeting Tumor Metabolism is one of the plenary sessions at the forthcoming AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Congress in San Francisco.
